Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | CDH1 | P12830 | 1/20 | 0.41 |
| ▸ | APC | P25054 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RXRG | P48443 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4681014 | 0.91 | NR1H4 (0.46) | KDM4EGAALMNAL3MBTL1RAB9A | |
| SCHEMBL10373895 | 0.80 | MEN1 (0.50) | KDM4EGAALMNAL3MBTL1RAB9A | |
| SCHEMBL4677882 | 0.79 | TDP1 (0.52) | KDM4EGAALMNAL3MBTL1RAB9A | |
| SCHEMBL20831970 | 0.73 | KDM4E (0.59) | KDM4EGAALMNAL3MBTL1RAB9A | |
| SCHEMBL115647 | 0.71 | LMNA (0.47) | KDM4EGAALMNAL3MBTL1RAB9A | |
| SCHEMBL8016751 | 0.71 | L3MBTL1 (0.91) | KDM4EGAALMNAL3MBTL1RAB9A | |
| SCHEMBL23542906 | 0.71 | KDM4E (0.68) | KDM4EGAALMNAL3MBTL1ADORA2A | |
| SCHEMBL29446663 | 0.71 | KDM4E (0.68) | KDM4EGAALMNAL3MBTL1ADORA2A | |
| SCHEMBL20831969 | 0.70 | ADORA2A (0.52) | KDM4EGAALMNAL3MBTL1RAB9A | |
| SCHEMBL7556164 | 0.69 | KDM4E (0.60) | KDM4EGAALMNAL3MBTL1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638953-B1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070099923-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099923-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099923-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| EP-1701958-B1 | PYRROLO-PYRAZINE DERIVATIVES USEFUL AS CB1-MODULATORS | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| EP-1701958-B1 | PYRROLO-PYRAZINE DERIVATIVES USEFUL AS CB1-MODULATORS | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1701958-A2 | PYRROLO-PYRAZINE DERIVATIVES USEFUL AS CB1-MODULATORS | AstraZeneca AB (SE) | 2006-09-20 | — | — | EP | disclosed |
| EP-1638956-A1 | 2,3-SUBSTITUTED 5,6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| EP-1638953-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005051953-A2 | PYRROLO-PYRAZINE DERIVATIVES USEFUL AS CB1-MODULATORS | ASTRAZENECA AB (SE) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004111034-A1 | 3-SUBSTITUTED 5,6-DIARYL-PYRAZINE-2-CARBOXAMIDE AND -2-SULFONAMIDE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004111039-A1 | 2,3-SUBSTITUTED 5,6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATORS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093505-A1 | 2,3-Substituted 5,6-diaryl-pyrazine derivatives as cb1 modulators | CNR2, CNR1, HTR2C | KDM4E 740/4885GAA 4036/4885LMNA 4331/4885 |
| US-20070093484-A1 | 3-Substituted 5,6-diaryl-pyrazine-2-carboxamide and -2-sulfonamide derivatives as cb1 modulators | CNR2, CNR1, FAAH | KDM4E 775/4885GAA 3433/4885LMNA 4233/4885 |
| US-20070099923-A1 | Therapeutic agents | CBR1, CBR3, CNR1 | KDM4E 2830/4885GAA 1588/4885LMNA 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.